Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MITF | O75030 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 10/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RNF4 | P78317 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876843 | 0.85 | CNR1 (0.50) | NPC1RAB9AHTTSMN1; SMN2CNR1 | |
| SCHEMBL8868001 | 0.81 | NPC1 (0.58) | NPC1RAB9AMITFALDH1A1HTT | |
| SCHEMBL6708022 | 0.80 | L3MBTL1 (0.49) | NPC1RAB9ASMN1; SMN2CNR1KDM4E | |
| SCHEMBL9081388 | 0.80 | NPC1 (0.76) | NPC1RAB9AMITFALDH1A1HTT | |
| SCHEMBL10616270 | 0.79 | POLB (0.57) | NPC1RAB9AMITFALDH1A1HTT | |
| SCHEMBL23928112 | 0.79 | RAB9A (0.61) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11128513 | 0.78 | NPC1 (0.63) | NPC1RAB9AMITFALDH1A1HTT | |
| SCHEMBL16626939 | 0.78 | NAMPT (0.61) | NPC1RAB9AMITFALDH1A1HTT | |
| SCHEMBL19876845 | 0.78 | CA2 (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2CNR1 | |
| SCHEMBL23928218 | 0.78 | NPC1 (0.60) | NPC1RAB9AALDH1A1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo (NO) | 2019-03-12 | — | — | US | disclosed |
| EP-3052135-B1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIV OSLO (NO) | 2018-07-18 | — | — | EP | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| EP-3052135-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | Universitetet I Oslo (NO) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049546-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIVERSITETET I OSLO (NO) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | NPC1 764/4885RAB9A 2718/4885MITF 3459/4885 |
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | SLC30A6, DDO, SLC30A7 | NPC1 764/4885RAB9A 2718/4885MITF 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.